Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Panel OKs Online Sales of Behind-the-Counter Drugs, but with Pharmacists’ Online Supervision
August 9, 2023
- Approve 16 Pediatric Cancer Meds as Exceptional Step Beyond Law, Oncologist Urges
August 8, 2023
- Novartis’ siRNA Dyslipidemia Therapy and More Up for Panel Review on August 21
August 8, 2023
- MHLW Panel to Review Alzheimer’s Med Lecanemab on August 21
August 8, 2023
- Japan Adopts New Evaluation Method for Nitrosamine Impurities Risks
August 7, 2023
- Japan’s Healthcare Spending Up 11.0% in FY2021: IPSS Report
August 7, 2023
- Despite Increase in Reviewers, Japan Faces Backlog of Over 4,000 Health Damage Claims for COVID Jabs
August 4, 2023
- With Generics Now in Common Use, It’s Time for Debate on LLP Copay: Payers
August 4, 2023
- Japan to Set Up New Forum on Dementia Measures: PM
August 4, 2023
- 30% of Eligible Population Unaware of HPV Vaccine: Survey
August 4, 2023
- Payers Want Phase-Out of Medical Fee Premiums for Generic Use; HCPs Eye Change in Entry Pricing
August 3, 2023
- Chuikyo OKs Plan to Move Back Medical Fee Revisions to June from FY2024; Drug Price Updates to Remain in April
August 3, 2023
- Industry Calls for Excluding Orphan Drugs from Cost-Effectiveness Assessment
August 3, 2023
- Chuikyo Reps Criticize Manufacturers’ Price Cuts after Unprofitability Re-Pricing
August 3, 2023
- Relief Claims OK’ed for 38 More Deaths after COVID Vaccination
August 2, 2023
- Generics Panel Initiates Debate toward Proposing Stable Supply Measures, Interim Report Slated for October
August 1, 2023
- Pharma Regulation Panel to Discuss Need for PI Japanese Data on Aug. 7
August 1, 2023
- Perjeta/Herceptin SC Combo, 1st Stelara, G-Lasta Biosimilars in Line for Japan Approval
August 1, 2023
- Japan Panel Shelves Decision on Shionogi’s COVID Vaccine over Efficacy Data
August 1, 2023
- First Two Homegrown COVID-19 Jabs Up for MHLW Panel Review on July 31
July 31, 2023
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…